June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Ocular Pharmacokinetics of 0.2% and 0.4% Ketorolac Tromethamine Formulated in DuraSite or DuraSite 2 Delivery Systems Compared to Acular LS in Rabbits
Author Affiliations & Notes
  • Afshin Shafiee
    Preclinical, InSite Vision, Alameda, CA
  • Lyle Bowman
    Development, InSite Vision, Alameda, CA
  • Eddie Hou
    Development, InSite Vision, Alameda, CA
  • Kamran Hosseini
    Preclinical, InSite Vision, Alameda, CA
    Clinical, InSite Vision, Alameda, CA
  • Footnotes
    Commercial Relationships Afshin Shafiee, InSite Vision (E); Lyle Bowman, InSite Vision (E); Eddie Hou, InSite Vision (E); Kamran Hosseini, InSite Vision Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 116. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Afshin Shafiee, Lyle Bowman, Eddie Hou, Kamran Hosseini; Ocular Pharmacokinetics of 0.2% and 0.4% Ketorolac Tromethamine Formulated in DuraSite or DuraSite 2 Delivery Systems Compared to Acular LS in Rabbits. Invest. Ophthalmol. Vis. Sci. 2013;54(15):116.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the ocular penetration of 0.2% and 0.4% ketorolac formulated in DuraSite or the new generation, DuraSite 2, delivery systems to Acular LS (0.4% ketorolac).

Methods: The left eye of male and female rabbits (n=32/group) received either a single topical instillation of ketorolac 0.2% or ketorolac 0.4% formulated in DuraSite, or DuraSite 2, or Acular LS. At predetermined timepoints (0.25, 0.5, 1, 2, 4, 6, 12, and 24 hours), 4 rabbits/group/timepoint were sacrificed and the ketorolac levels in the aqueous humor (AH) were quantified using LC-MS/MS methodology. PK parameters (Cmax, Tmax, AUC0.25-24h) were determined.

Results: Ketorolac 0.4% formulated in DuraSite 2 achieved the highest Cmax (1889 ± 884 ng/mL) and AUC (6836 ng/mL*h) values, an increase of 6.9- and 4.8-fold over Acular LS which had the lowest Cmax (275 ± 83 ng/mL) and AUC (1424 ng/mL*h) values, respectively. Ketorolac 0.2% formulated in DuraSite 2 had Cmax (1077 ± 415 ng/mL) and AUC (4490 ng/mL*h) values that were 3.9- and 3.2-fold higher than Acular LS, respectively. Ketorolac 0.2% and 0.4% formulated in DuraSite also provided better AH pharmacokinetics with Cmax values that were 2.9- and 4.4-fold higher than Acular LS, respectively, and AUC values that were 2.3- and 4.0-fold higher than Acular LS, respectively.

Conclusions: Ketorolac formulated in DuraSite markedly improved drug delivery kinetics to the AH compared with Acular LS; the new generation delivery system, DuraSite 2, showed enhanced penetration over DuraSite. DuraSite 2 formulation may allow a major reduction in the dosing regimen or lowering of the ketorolac levels in the ophthalmic formulation; it may potentially lessen the side effect profiles associated with the topical use of ketorolac.

Keywords: 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×